AnaptysBio Statistics
Share Statistics
AnaptysBio has 29.38M
shares outstanding. The number of shares has increased by 12.26%
in one year.
| Shares Outstanding | 29.38M |
| Shares Change (YoY) | 12.26% |
| Shares Change (QoQ) | 0.78% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,796 |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 8.96M, so 30.5% of the outstanding
shares have been sold short.
| Short Interest | 8.96M |
| Short % of Shares Out | 30.5% |
| Short % of Float | 55.05% |
| Short Ratio (days to cover) | 15.56 |
Valuation Ratios
The PE ratio is -2.59 and the forward
PE ratio is -4.03.
AnaptysBio's PEG ratio is
0.16.
| PE Ratio | -2.59 |
| Forward PE | -4.03 |
| PS Ratio | 4.12 |
| Forward PS | 4.5 |
| PB Ratio | 5.3 |
| P/FCF Ratio | -2.77 |
| PEG Ratio | 0.16 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for AnaptysBio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.51,
with a Debt / Equity ratio of 0.23.
| Current Ratio | 9.51 |
| Quick Ratio | 9.51 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.12 |
| Interest Coverage | -2.29 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $671,176.47 |
| Profits Per Employee | $-1,067,875 |
| Employee Count | 136 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 3K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -18.73% in the
last 52 weeks. The beta is -0.2, so AnaptysBio's
price volatility has been lower than the market average.
| Beta | -0.2 |
| 52-Week Price Change | -18.73% |
| 50-Day Moving Average | 18.66 |
| 200-Day Moving Average | 23.86 |
| Relative Strength Index (RSI) | 55.51 |
| Average Volume (20 Days) | 1,019,526 |
Income Statement
In the last 12 months, AnaptysBio had revenue of 91.28M
and earned -145.23M
in profits. Earnings per share was -5.12.
| Revenue | 91.28M |
| Gross Profit | 88.88M |
| Operating Income | -114.95M |
| Net Income | -145.23M |
| EBITDA | -92.74M |
| EBIT | -95.14M |
| Earnings Per Share (EPS) | -5.12 |
Full Income StatementBalance Sheet
The company has 123.08M in cash and 16.04M in
debt, giving a net cash position of 107.04M.
| Cash & Cash Equivalents | 123.08M |
| Total Debt | 16.04M |
| Net Cash | 107.04M |
| Retained Earnings | -759.33M |
| Total Assets | 422.05M |
| Working Capital | 319.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -135.34M
and capital expenditures -358K, giving a free cash flow of -135.69M.
| Operating Cash Flow | -135.34M |
| Capital Expenditures | -358K |
| Free Cash Flow | -135.69M |
| FCF Per Share | -4.78 |
Full Cash Flow StatementMargins
Gross margin is 97.37%, with operating and profit margins of -125.93% and -159.1%.
| Gross Margin | 97.37% |
| Operating Margin | -125.93% |
| Pretax Margin | -159.1% |
| Profit Margin | -159.1% |
| EBITDA Margin | -101.6% |
| EBIT Margin | -125.93% |
| FCF Margin | -148.66% |
